- Home
- SMTI
SMTI
Sanara MedTech Inc.
as 04-01-2025 3:42pm EST
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | FORT WORTH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $48.50 | AVG Volume (30 days): | 22.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.00 - $39.08 | Next Earning Date: | 03-25-2025 |
| Revenue: | $86,672,425 | Revenue Growth: | 33.36% |
| Revenue Growth (this year): | 22.51% | Revenue Growth (next year): | 8.17% |
Latest Sanara MedTech Inc. News
SMTI Breaking Stock News: Dive into SMTI Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Sanara MedTech Full Year 2024 Earnings: EPS Misses Expectations
GuruFocus.com
7 days ago
Sanara MedTech Inc (SMTI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
GlobeNewswire
8 days ago
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
GuruFocus.com
9 days ago
Earnings To Watch: Sanara MedTech Inc (SMTI) Reports Q4 2024 Result
GlobeNewswire
22 days ago
Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Simply Wall St.
a month ago
Investors in Sanara MedTech (NASDAQ:SMTI) have seen strong returns of 215% over the past five years
GlobeNewswire
2 months ago
Biomimetic Innovations Ltd, an affiliate of PBC Biomed, Announces an Exclusive License and Distribution Agreement and Minority Investment with Sanara MedTech Inc.
GlobeNewswire
2 months ago
Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd
Compare SMTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SMTI Sanara MedTech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.